GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » Price-to-Owner-Earnings

InterMune (FRA:IUX) Price-to-Owner-Earnings : (As of Jun. 22, 2024)


View and export this data going back to . Start your Free Trial

What is InterMune Price-to-Owner-Earnings?

As of today (2024-06-22), InterMune's share price is €58.06. InterMune does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for InterMune's Price-to-Owner-Earnings or its related term are showing as below:


FRA:IUX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.85
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-22), InterMune's share price is €58.06. InterMune's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2014 was €-1.90. Therefore, InterMune's PE Ratio for today is At Loss.

As of today (2024-06-22), InterMune's share price is €58.06. InterMune's EPS without NRI for the trailing twelve months (TTM) ended in was €-1.92. Therefore, InterMune's PE Ratio without NRI for today is At Loss.

During the past 13 years, InterMune's highest PE Ratio without NRI was 53.39. The lowest was -30.24. And the median was 44.31.


InterMune Price-to-Owner-Earnings Historical Data

The historical data trend for InterMune's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InterMune Price-to-Owner-Earnings Chart

InterMune Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

InterMune Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InterMune's Price-to-Owner-Earnings

For the Biotechnology subindustry, InterMune's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InterMune's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InterMune's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where InterMune's Price-to-Owner-Earnings falls into.



InterMune Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

InterMune's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=58.06/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InterMune  (FRA:IUX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


InterMune Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of InterMune's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


InterMune (FRA:IUX) Business Description

Traded in Other Exchanges
N/A
Address
InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

InterMune (FRA:IUX) Headlines

No Headlines